CD8A and cancer: In contrast to a previous study reporting that Ipi therapy broadens the repertoire of melanoma-reactive CD8+ T-cells in cancer patients [26], the rDNA-SIVnfl+Ipi immunizations appeared to restrict the breadth of vaccine-induced SIV-specific CD8+ T-cells in Group 2 (Fig 6C).